Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis

Cephalalgia

Volumn 35, Issue 5, 2015, Pages 379-388

  Chabi, Almira ^a   Zhang, Ying ^a   Jackson, Saheeda ^a   Cady, Roger ^b   Lines, Christopher ^a   Herring, W Joseph ^a   Connor, Kathryn M ^a   Michelson, David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b HEADACHE CARE CENTER   (United States)

Author keywords

Filorexant; migraine; MK 6096; orexin; prophylaxis

Indexed keywords

CREATINE KINASE; FILOREXANT; OREXIN; OREXIN RECEPTOR; MK-6096; OREXIN RECEPTOR ANTAGONIST; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ANALGESIC ACTIVITY; AROUSAL; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NIGHTMARE; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SLEEP TIME; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; MIGRAINE DISORDERS;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; OREXIN RECEPTOR ANTAGONISTS; PIPERIDINES; PYRIMIDINES;

EID: 84924765911     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102414544979     Document Type: Article

References (29)

1. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001 ; 358: 1668-1675
2. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010 ; 6: 573-582
3. Färkkilä M, Diener HC, Géraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012 ; 11: 405-413
4. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 ; 68: 343-349
5. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998 ; 95: 322-327
6. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998 ; 92: 573-585
7. Sakurai T, Mieda M, Tsujino N. The orexin system: Roles in sleep/wake regulation. Ann N Y Acad Sci. 2010 ; 1200: 149-161
8. Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant. Neurology. 2012 ; 79: 2265-2274
9. Hoever P, Dorffner G, Beneš H, et al. Orexin receptor antagonism, a new sleep-enabling paradigm: A proof-of-concept clinical trial. Clin Pharmacol Ther. 2012 ; 91: 975-985
10. Holland P, Goadsby PJ. The hypothalamic orexinergic system: Pain and primary headaches. Headache. 2007 ; 47: 951-962
11. Bigal ME, Hargreaves RJ. Why does sleep stop migraine?. Curr Pain Headache Rep. 2013 ; 17: 369-369
12. Andress-Rothrock D, King W, Rothrock J. An analysis of migraine triggers in a clinic-based population. Headache. 2010 ; 50: 1366-1370
13. Wilkinson M. Migraine treatment: The British perspective. Headache. 1994 ; 34: S13 - S16
14. Martins IP, Parreira E. Behavioral response to headache: A comparison between migraine and tension-type headache. Headache. 2001 ; 41: 546-553
15. Bartsch T, Levy MJ, Knight YE, et al. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain. 2004 ; 109: 367-378
16. Holland PR, Akerman S, Goadsby PJ. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci. 2006 ; 24: 2825-2833
17. Hoffman J, Supronsinchai W, Akerman S, et al. Nociceptive trigeminal neurotransmission is inhibited by the dual orexin receptor antagonist DORA-12. Cephalalgia. 2013 ; 33 (Suppl). 8-9
18. Sun H, Brown K, Calder N, et al. MK-6096, a dual orexin receptor antagonist, enhances sleep onset and maintenance as measured by PSG in healthy male subjects. Sleep Biol Rhythms. 2011 ; 9: 334-334
19. Coleman PJ, Schreier JD, Cox CD, et al. Discovery of [(2R,5R)-5-{[(5-fluoropyridin 2yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2yl)phenyl]methanone (MK-6096): A dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem. 2012 ; 7: 415-424
20. Winrow CJ, Gotter AL, Cox CD, et al. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. Neuropharmacology. 2012 ; 62: 978-987
21. Connor KM, Mahoney E, Jackson S, et al. A dual orexin receptor antagonist, MK-6096, in patients with primary insomnia: Randomized, controlled, crossover polysomnography study. Sleep Biol Rhythms. 2011 ; 9: 332-332
22. Connor KM, Zhao X, Mahoney E, et al. MK-6096, a dual orexin receptor antagonist, improves subjective measures of sleep and functioning in adults with primary insomnia. Neuropsychopharmacology. 2011 ; 36 (Suppl 1S). S233 - S233
23. The International Classification of Headache Disorders (second edition). Cephalalgia. 2004 ; 24 (Suppl 1). 1-160
24. Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Indian J Stat. 2000 ; 62 (Series B, Pt 1). 134-148
25. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: A randomized controlled trial. JAMA. 2004 ; 291: 965-973
26. Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology; in press.
27. Bussone G, Diener H-C, Pfeil J, et al. Topiramate 100 mg/day in migraine prevention: A pooled analysis of double-blinded randomised controlled trials. Int J Clin Pract. 2005 ; 59: 961-968
28. Hoever P, de Haas S, Winkler J, et al. Orexin receptor antagonism, a new sleep-promoting paradigm: An ascending single-dose study with almorexant. Clin Pharmacol Ther. 2010 ; 87: 593-600
29. Sun H, Kennedy WP, Wilbraham D, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013 ; 36: 259-267